Connect with us

Health

New Parkinson's drug could slow or reverse progression of disease, researchers say: 'Big step forward'

Published

on

New Parkinson's drug could slow or reverse progression of disease, researchers say: 'Big step forward'

A new drug is being tested to relieve Parkinson’s disease (PD) symptoms – and it’s reportedly showing promise.

The drug is designed to slow or halt the progression of the disease in patients by targeting toxic proteins that build up in the brain, according to the study published in the journal Nature Medicine on June 20.

Researchers conducted a phase 1 placebo-controlled trial of an investigational immunotherapy drug called UB-312, testing for safety, tolerability and immunogenicity (strength of immune response).

AI BLOOD TEST COULD DETECT PARKINSON’S DISEASE UP TO 7 YEARS BEFORE SYMPTOMS: ‘PARTICULARLY PROMISING’

The trial results showed that the drug was generally safe and well-tolerated by patients as a disease-modifying treatment for Parkinson’s.

Advertisement

The researchers stated that to their knowledge, this is the first report showing a positive effect of an investigational therapy of this kind.

In a new study, Parkinson’s patients reported improved daily movement after being administered UB-312. (iStock)

There is currently no cure for Parkinson’s, only drugs that treat the symptoms.

“UB-312 is designed to modify the course of Parkinson’s disease by targeting the underlying cause,” Lou Reese, co-founder of Vaxxinity, the Texas-based pharmaceutical company that worked on the study, told Fox News Digital.

Leiden University Medical Centre in the Netherlands, University of Texas McGovern Medical School, and Mayo Clinic in Rochester, Minnesota, also helped conduct the study.

Advertisement

MILITARY VETERAN EMBRACES ‘NEW SERVICE’ OF HELPING OTHERS AFTER HIS PARKINSON’S DIAGNOSIS: ‘THERE IS HOPE’

“In our phase 1 trial, we showed that UB-312 may be able to stop or even reverse the course of disease by successfully targeting aggregated alpha-synuclein.” 

(Alpha-synuclein is an acidic protein that builds up in the brains of Parkinson’s patients.)

UB-312 is given as an injection, typically via multiple doses over several months, Reese noted.

“Time and science will help us to determine if this newer approach will fare better.”

Advertisement

During the trial, PD patients reported improved daily movement after receiving the new drug.

The medication was found to be safe and well-tolerated in healthy people and Parkinson’s patients alike, with only minimal side effects that included headaches and fatigue, according to Reese.

The drug UB-312 is administered via injection, typically via multiple doses over several months. (iStock)

UB-312 works by targeting the “harmful Parkinson’s protein” alpha-synuclein and producing antibodies against it, the researcher said.

In the trial, 12 out of 13 patients developed antibodies, which Reese described as a “big step forward in PD treatment.”

Advertisement

RESEARCHERS FIND SOURCES OF FOUR BRAIN DISORDERS, WHICH COULD LEAD TO NEW TREATMENTS

“These antibodies reached the brain and interacted with the target protein,” he said.

Based on the “promising” results of Phase 1, UB-312 will now progress into phase 2 trials, focusing on a larger patient population while optimizing the dose, according to Reese.

Alpha-synuclein antibodies “reached the brain and interacted with the target protein,” the researcher said. (iStock)

“The ultimate goal is to develop effective, disease-modifying treatments that can improve outcomes and provide hope for individuals living with Parkinson’s disease,” he added.

Advertisement

For more Health articles, visit www.foxnews/health 

“This is exciting because we are targeting the root cause of Parkinson’s and not the symptoms. It’s the first drug ever to take a patient from positive to negative.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Some doctors, however, cautioned that Parkinson’s patients shouldn’t get their hopes up just yet.

“People with Parkinson’s should be aware that although the findings were interesting, this was only a safety, tolerability and immunogenicity study, and thus there is a long way to go for development of this treatment,” Michael S. Okun, M.D., Parkinson’s Foundation medical adviser and director at the Norman Fixel Institute for Neurological Diseases at the University of Florida Health, told Fox News Digital.

Advertisement

Scientists “worry” that this approach may not improve outcomes or slow disease progression, one doctor told Fox News Digital. (iStock)

Okun was not involved in the study.

The injections did seem to “rev up the immune system,” Okun acknowledged, as the researchers observed the appearance of antibodies in the blood samples of most study participants.      

“The worry that many scientists have about this approach is that it may neither improve clinical outcomes nor slow disease progression,” he added.

Advertisement

“Two similar antibody trials of prasinezumab and cinpanemab were published in 2022 in The New England Journal of Medicine, but both of those trials failed to meet their primary outcomes.”

Okun concluded that “time and science will help us to determine if this newer approach will fare better.”

Advertisement

Health

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause

Published

on

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause


Advertisement




Melissa Joan Hart Opens up About Weight Loss in Perimenopause | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Alzheimer’s prevention breakthrough found in decades-old seizure drug

Published

on

Alzheimer’s prevention breakthrough found in decades-old seizure drug

NEWYou can now listen to Fox News articles!

A drug that has long been used to treat seizures has shown promise as a potential means of Alzheimer’s prevention, a new study suggests.

The anti-seizure medication, levetiracetam, was first approved by the FDA in November 1999 under the brand name Keppra as a therapy for partial-onset seizures in adults. The approval has since expanded to include children and other types of seizures.

Northwestern University researchers recently found that levetiracetam prevented the formation of toxic amyloid beta peptides, which are small protein fragments in the brain that are commonly seen in Alzheimer’s patients.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons, according to the study findings, which were published in Science Translational Medicine.

Advertisement

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons. (iStock)

“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid‑beta 42 peptides and amyloid plaques,” said corresponding author Jeffrey Savas, associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine, in a press release. 

“Our new results uncovered new biology while also opening doors for new drug targets.”

HIDDEN BRAIN CONDITION MAY QUADRUPLE DEMENTIA RISK IN OLDER ADULTS, STUDY SUGGESTS

Advertisement

The brain is better able to avoid the pathway that produces toxic amyloid‑beta 42 proteins in younger years, but the aging process gradually weakens that ability, Savas noted. 

“This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he said. 

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease. (iStock)

That then leads to tau (“tangles”) — abnormal clumps of protein inside brain neurons — which can kill brain cells, trigger neuroinflammation and lead to dementia.

In order for levetiracetam to function as an Alzheimer’s blocker, high-risk patients would have to start taking it “very, very early,” Savas said — up to 20 years before elevated amyloid-beta 42 levels would be detected.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death,” the researcher noted.

The researchers also did a deep dive into previous human clinical data to determine whether Alzheimer’s patients who were taking the anti-seizure drug had slower cognitive decline. They reported that the patients in that category had a “significant delay” in the span from cognitive decline to death compared to those not taking the drug.

“This analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” the researcher said. (iStock)

“Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas said.

Advertisement

Looking ahead, the research team aims to find people who have genetic forms of Alzheimer’s to participate in testing, Savas said.

Limitations and caveats

The study had several limitations, including that it relied on animal models and cultured cells, with no human trials conducted.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Because the study was observational in nature, it can’t prove that the medication caused the prevention of the toxic brain proteins, the researchers acknowledged.

Savas noted that levetiracetam “is not perfect,” cautioning that it breaks down in the body very quickly.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The team is currently working to create a “better version” that would last longer in the body and “better target the mechanism that prevents the production of the plaques.”

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death.”

The medication’s common documented side effects include drowsiness, weakness, dizziness, irritability, headache, loss of appetite and nasal congestion.

It has also been linked to potential mood and behavior changes, including anxiety, depression, agitation and aggression, according to the prescribing information. In rare cases, it could lead to severe allergic reactions, skin reactions, blood disorders and suicidal ideation.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Funding for the study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund.

Fox News Digital reached out to the drug manufacturer and the researchers for comment.

Related Article

Alzheimer’s decline could slow dramatically with one simple daily habit, study finds
Continue Reading

Health

Seniors over 80 who eat specific diet may be less likely to reach 100 years old

Published

on

Seniors over 80 who eat specific diet may be less likely to reach 100 years old

NEWYou can now listen to Fox News articles!

Older adults who avoid meat in their golden years may be less likely to reach age 100 than their meat-eating counterparts, new research suggests.

Researchers tracked more than 5,000 adults aged 80 or older who were enrolled in the Chinese Longitudinal Healthy Longevity Survey.

Between 1998 and 2018, data showed that those who did not eat meat were less likely to reach their 100th birthday than those who consumed animal products regularly.

The findings seem to contradict previous studies that have linked vegetarianism and plant-based diets to lower risks of heart disease, stroke, diabetes and obesity.

Advertisement

Most evidence supporting the benefits of plant-based diets comes from studies tracking younger populations, the researchers noted. 

The findings contrast with previous research praising plant-based diets for their positive influence on heart health. (iStock)

The study, published in The American Journal of Clinical Nutrition, points to losses in muscle mass and bone density with age, shifts that can increase the risk of malnutrition and frailty in the “oldest old.”

As people enter their 80s and 90s, the nutritional priority often shifts from preventing long-term chronic diseases to maintaining day-to-day physical function, experts say.

HOW MUCH RED MEAT IS TOO MUCH? EXPERTS WEIGH IN ON FOOD PYRAMID UPDATES

Advertisement

“The headline ‘vegetarians over 80 less likely to reach 100’ sounds surprising, because it contrasts with decades of data linking plant‑forward diets to lower chronic disease risk earlier in life,” Erin Palinski-Wade, a New Jersey-based registered dietitian, told Fox News Digital. 

“However, once you see that this research is limited to adults over the age of 80 who are also underweight — and that this link disappears with the consumption of eggs, dairy and fish — the results are less surprising.”

While diets earlier in life tend to emphasize avoiding long-term disease, older age necessitates nutrients and weight maintenance, experts say. (iStock)

In those over 80, restricting animal proteins may be less likely to promote longevity, according to Palinski-Wade, who was not involved in the study.

Eliminating all animal protein — particularly in a population that may already experience diminished hunger cues — can make it more difficult to meet adequate protein needs, potentially increasing the risk of nutrient deficiencies, the nutritionist said.

Advertisement

ALZHEIMER’S SYMPTOMS COULD BE PREDICTED YEARS IN ADVANCE THROUGH ONE SIMPLE TEST

In addition to a higher tendency to be underweight, older populations also face a greater risk of bone fractures due to lower calcium and protein intake.

Potential limitations

The lower rate of vegetarians reaching 100 was only observed in participants identified as underweight, the researchers noted. No such association was found in people who maintained a healthy weight.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Because being underweight is already linked to greater frailty and mortality risk, the researchers noted that body weight may partly explain the findings, making it difficult to determine whether diet itself played a direct role.

Advertisement

Those incorporating animal-sourced products other than meat were just as likely to live to 100. (iStock)

Additionally, the shortened lifespans were not found in people who continued to eat non-meat animal products, such as fish, dairy and eggs. 

Older adults with these more flexible diets were just as likely to live to 100 as those eating meat, as these foods may provide the nutrients necessary for maintaining muscle and bone health, the researchers noted.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“This is an observational study, so it can only show associations, and does not prove that avoiding meat directly reduces the odds of reaching 100,” Palinski-Wade added.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

The researchers suggested that including small amounts of animal-sourced foods could help older seniors maintain essential nutrients and avoid the muscle loss often seen in those who stick strictly to plants.

Eliminating all animal protein — particularly in a population that may already experience diminished hunger cues — can make it more difficult to meet adequate protein needs, potentially increasing the risk of nutrient deficiencies. (iStock)

Palinski-Wade offered some guidance for those looking to optimize nutrition later in life.

“For adults in their 80s and beyond, especially anyone losing weight or muscle, the priority should be maintaining a healthy weight and meeting protein and micronutrient needs — even if that means adding or increasing fish, eggs, dairy or well‑planned, fortified plant proteins and supplements.”

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Strict vegan or very low‑protein patterns at that age should be carefully monitored by a dietitian or clinician, with attention to B12, vitamin D, calcium and total protein, according to Palinski-Wade.

“Younger and healthier adults can still confidently use plant‑forward or vegetarian patterns to lower long‑term chronic disease risk,” she added.

Related Article

Scientists reveal the one practice that could prevent dementia as you age
Continue Reading

Trending